Goldman Sachs Group Incinsider trades
In SEC Form 4 filings, Goldman Sachs Group Inc is listed as Reporting owner of Attovia Therapeutics, Inc. (ATTO). In the last 90 days, Goldman Sachs Group Inc bought $10.29M of Attovia Therapeutics, Inc. (ATTO) and sold $2.25M of Attovia Therapeutics, Inc. (ATTO) on the open market. The largest purchase was $8.50M of Attovia Therapeutics, Inc. (ATTO) on Aug 6. Took part in a cluster buy; the latest at Attovia Therapeutics, Inc. (ATTO), where 2 insiders bought within 2 days, ending Aug 6.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| ATTOAttovia Therapeutics, Inc. | Reporting owner | 35 | Aug 28 |
Cluster buys
- ATTO: 2 insiders bought $20.57M between Aug 5 – Aug 6.
Form 4 historysince 2026-08-28
Dashed line = amended filing (Form 4/A)
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| ATTOAttovia Therapeutics, Inc. | Aug 6 | Aug 284/A | C | 1,957,134 | $0.00 | $0 | 2,042,134 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 6 | Aug 284/A | C | 478,498 | $0.00 | $0 | 2,520,632 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 6 | Aug 284/A | P | 500,000 | $17.00 | Purchase +$8,500,000 | 3,020,632 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 6 | Aug 284/A | C · derivative | 18,181,830 | $0.00 | $0 | not reported | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 6 | Aug 284/A | C · derivative | 4,445,275 | $0.00 | $0 | not reported | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | P | 85,000 | $21.00 | Purchase +$1,785,000 | 85,000 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 988 | $22.03 | Sale −$21,766 | 84,012 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 447 | $21.87 | Sale −$9,776 | 83,565 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 1,332 | $22.03 | Sale −$29,344 | 82,233 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 200 | $22.05 | Sale −$4,410 | 82,033 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 1,556 | $22.06 | Sale −$34,325 | 80,477 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 3,402 | $22.02 | Sale −$74,912 | 77,075 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 200 | $22.10 | Sale −$4,420 | 76,875 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 480 | $21.55 | Sale −$10,344 | 76,395 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 100 | $22.11 | Sale −$2,211 | 76,295 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 753 | $21.97 | Sale −$16,543 | 75,542 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 672 | $22.02 | Sale −$14,797 | 74,870 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 6,970 | $22.03 | Sale −$153,549 | 67,900 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 400 | $22.02 | Sale −$8,808 | 67,500 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 1,180 | $21.84 | Sale −$25,771 | 66,320 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 1,040 | $22.05 | Sale −$22,932 | 65,280 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 300 | $20.84 | Sale −$6,252 | 64,980 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 443 | $21.78 | Sale −$9,649 | 64,537 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 200 | $22.05 | Sale −$4,410 | 64,337 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 700 | $22.07 | Sale −$15,449 | 63,637 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 1,163 | $22.19 | Sale −$25,807 | 62,474 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 100 | $21.99 | Sale −$2,199 | 62,374 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 6,763 | $21.61 | Sale −$146,148 | 55,611 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | S | 76,418 | $21.04 | Sale −$1,607,835 | not reported | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | P · derivative | 2,872 | $21.22 | Purchase +$60,944 | 2,872 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | P · derivative | 28,717 | $21.22 | Purchase +$609,375 | 31,589 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | P · derivative | 11,488 | $21.22 | Purchase +$243,775 | 43,077 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | P · derivative | 45,588 | $21.27 | Purchase +$969,657 | 88,665 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | P · derivative | 11,398 | $21.27 | Purchase +$242,435 | 100,063 | No | Form 4/A |
| ATTOAttovia Therapeutics, Inc. | Aug 5 | Aug 284/A | P · derivative | 5,744 | $21.22 | Purchase +$121,888 | 105,807 | No | Form 4/A |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.